

*Nebraska; and Travis J. Tessendorf, Columbus, Nebraska; as a group acting in concert, to acquire voting shares of Bellwood Community Holding Company, and indirectly acquire shares of Bank of the Valley, both in Bellwood, Nebraska.*

*B. Federal Reserve Bank of St. Louis* (David L. Hubbard, Senior Manager) P.O. Box 442, St. Louis, Missouri 63166–2034 or electronically to *Comments.applications@stls.frb.org*:

*1. The 2019 Mark Waldrip Beneficiary GST Trust, Mark Waldrip as trustee, Little Rock, Arkansas, and the 2019 Angela Waldrip Beneficiary GST Trust, Angela Waldrip and Nathan Waldrip as co-trustees, both of Moro, Arkansas; individually and as a group, to join the control group of Waldrip Bank Trust, Mark and Angela Waldrip as co-trustees, Nathan and Maegan Waldrip JTWRS, Allison and Aaron Bragg JTWRS, Katie and Ethan Branscum JTWRS, Lauren W. Ward, the 2017 Allison Waldrip Bragg Trust, Allison Bragg and Nathan Waldrip as co-trustees, the 2017 Nathan M. Waldrip Trust, Nathan Waldrip and Allison Bragg as co-trustees, the 2017 Katie Waldrip Branscum Trust, Katie Branscum and Allison Bragg as co-trustees and the 2017 Lauren Waldrip Ward Trust, Lauren Ward and Nathan Waldrip as co-trustees, all of Little Rock, Arkansas, to retain more than 25 percent of the voting shares of Big Creek Bancshares, Inc., Mariana, Arkansas.*

Board of Governors of the Federal Reserve System, August 23, 2019.

**Yao-Chin Chao,**  
*Assistant Secretary of the Board.*

[FR Doc. 2019–18640 Filed 8–28–19; 8:45 am]

**BILLING CODE P**

## FEDERAL RESERVE SYSTEM

### Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments

must be received not later than September 16, 2019.

*A. Federal Reserve Bank of St. Louis* (David L. Hubbard, Senior Manager) P.O. Box 442, St. Louis, Missouri 63166–2034 or electronically to *Comments.applications@stls.frb.org*:

*1. John M. Huetsch and Mary Ellen L. Huetsch, both of Waterloo, Illinois; John C. Huetsch and Christina T. Lai, both of Baltimore, Maryland; Mark A. Huetsch and Liang Wang, both of Beijing, China; Steve C. Huetsch, Columbia, Illinois; Randall L. Huetsch and Julie Huetsch, both of Chesterfield, Missouri; and Lynne M. Duren, Winchester, Illinois; as a group acting in concert, to retain voting shares of SBW Bancshares, Inc., Waterloo, Illinois, and thereby indirectly retain shares of State Bank of Waterloo, Waterloo, Illinois.*

Board of Governors of the Federal Reserve System, August 26, 2019.

**Yao-Chin Chao,**  
*Assistant Secretary of the Board.*

[FR Doc. 2019–18720 Filed 8–28–19; 8:45 am]

**BILLING CODE P**

indicated or the offices of the Board of Governors not later than September 27, 2019.

*A. Federal Reserve Bank of Richmond* (Adam M. Drimer, Assistant Vice President) 701 East Byrd Street, Richmond, Virginia 23219. Comments can also be sent electronically to or *Comments.applications@rich.frb.org*:

*1. Blue Ridge Bankshares, Inc., Luray, Virginia; to acquire 100 percent of the voting shares of Virginia Community Bankshares, Inc., and thereby indirectly acquire Virginia Community Bank, both of Louisa, Virginia.*

Board of Governors of the Federal Reserve System, August 23, 2019.

**Yao-Chin Chao,**  
*Assistant Secretary of the Board.*

[FR Doc. 2019–18641 Filed 8–28–19; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket No. CDC–2019–0069]

### Proposed Update of the CDC's 2006 Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice with comment period.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC) in the Department of Health and Human Services (HHS) is seeking public comment for updating the following guideline: Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings (2006). The purpose of this notice is to solicit feedback on best approaches on HIV screening in clinical settings and prompt linkage to treatment and care. CDC will update this guideline to ensure that HIV testing providers, public health agencies, and other stakeholders have access to up-to-date and consistent information about new evidence, current approaches, and resources for HIV testing in clinical settings.

**DATES:** Written comments must be received on or before October 28, 2019.

**ADDRESSES:** You may submit comments, identified by Docket No. CDC–2019–0069 by any of the following methods:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments.

- *Mail:* DHAP Guideline Team, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS D21, Atlanta, Georgia 30329.

**Instructions:** All submissions must include the agency name and Docket Number. All relevant comments received will be posted without change to <https://www.regulations.gov>, including any personal information provided. For access to the docket to read background documents or comments received, go to <https://www.regulations.gov>.

**FOR FURTHER INFORMATION CONTACT:**

Priya Jakhmola, Health Scientist, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS-D21, Atlanta, Georgia 30329. Telephone: 404-639-2495, Email: [dhapguideline@cdc.gov](mailto:dhapguideline@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

**Public Participation**

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. In addition, CDC invites comments specifically on opt-out routine HIV testing, including, but not limited to:

- Suggestions for revisions, edits, and new additions
- Contemporary issues and new evidence
- Implementation barriers, challenges, and lessons learned
- Examples of innovative models, partnerships, and collaborations

Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on <https://www.regulations.gov>. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information, inappropriate language, or examples of a mass-mail campaign. CDC will carefully consider all comments submitted in preparation of the final document and may revise the final document as appropriate.

**Background**

The CDC guideline “Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings” was published on September 22, 2006 in CDC’s *Morbidity and Mortality Weekly Report* (MMWR). Since then, there have been changes in evidence related to HIV testing technologies and interventions, disease epidemiology, outcomes, implementation resources, and related guidelines. This evidence will be identified, assessed, and analyzed to inform the update.

CDC will update the 2006 Guidelines based on input from subject matter experts, public health agencies, the public, and other stakeholders. The guideline development process will draw on up-to-date nationally and internationally accepted guideline development criteria, tools, and resources, including CDC guideline development standards. The process will include a rigorous systematic review of key questions formulated through the PICO (Patient-Intervention-Comparator-Outcome) method. PICO is the foundation of an evidence-based process and facilitates the search for relevant evidence by identifying key concepts and formulating a search strategy. Graded recommendations will be developed using quality and strength of underlying evidence.

Throughout the process of updating the guideline, there will be multiple opportunities for the public to comment on the drafts. We welcome input from a diverse range of perspectives, which will inform the development of the guideline, improve its credibility, and increase the transparency of the process.

Dated: August 26, 2019.

**Sandra Cashman,**

*Executive Secretary, Centers for Disease Control and Prevention.*

[FR Doc. 2019-18659 Filed 8-28-19; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**[Docket No. FDA-2018-D-3092]**

**Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products; Guidance for Industry; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products.” This guidance provides recommendations to industry about using placebos and blinding in randomized controlled clinical trials in development programs for drug or biological products to treat hematologic malignancies and oncologic diseases regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). This guidance finalizes the draft guidance entitled “Hematologic Malignancy and Oncologic Disease: Considerations for Use of Placebos and Blinding in Randomized Controlled Clinical Trials for Drug Product Development” issued August 24, 2018.

**DATES:** The announcement of the guidance is published in the **Federal Register** on August 29, 2019.

**ADDRESSES:** You may submit either electronic or written comments on Agency guidances at any time as follows:

**Electronic Submissions**

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

**Written/Paper Submissions**

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets